The present study suggests that the p53 signaling pathway is associated with the pathogenesis of IPF, and that PFD and NTD treatments may influence the p53 signaling pathway at the PBMC level, ultimately leading to suppressive effects on pulmonary fibrosis progression. Here, TP53 is linked to idiopathic pulmonary fibrosis.